Here are three things to know:
1. LifeScan, which produces blood glucose monitoring products, recorded $1.5 billion in net revenue in 2017.
2. J&J announced a strategic review of its diabetes businesses last year, and the company officially shut down its insulin pump unit, Animas, in October.
3. The deal is expected to close by the end of 2018.
More articles on supply chain:
Pharmacist recommended: 30 top OTC health products of 2018
Novo Nordisk considers 3k layoffs amid turbulence in US insulin market
Bayer hikes price of 2 cancer drugs by $1k per month
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.